We postulated that PD-L1-MSA treatment could effectively attenuate T cell activation by blocking the interference of sPD-1 with the PD-1/PD-L1 axis, thereby alleviating the inflammatory response and mitigating arthritis development in mice. The gene discussed is HOXD13; the disease is arthritic joint disease.